YTE-001 is under clinical development by China Immunotech and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase I drugs for Hemophagocytic Lymphohistiocytosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YTE-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of Epstein Barr virus (EBV) infections after hematopoietic stem cell transplantation (HSCT), EBV-associated hemophagocytic lymphohistiocytosis and EBV-positive, refractory nasopharyngeal carcinoma. The therapeutic candidate consists of lentivirus and comprises of genetically engineered allogenic T-cells to express virus specific T-cell receptor (TCR). It is administered through intravenous route. The therapeutic candidate acts by targeting EBV antigen such as LMP1, LMP2 and EBNA1.
China Immunotech overview
China Immunotech (Beijing) Biotechnology Co., Ltd., a biotechnology company that engaged in biopharmaceutics research and development. The company is headquartered in China.
For a complete picture of YTE-001’s drug-specific PTSR and LoA scores, buy the report here.